Jessica Wisdom
Family · Dothan, ALNPI 1811628639
Payments from drug & device makers
Across 146 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$610
- Boehringer Ingelheim$231
- Lilly USA, LLC$214
- RGH Enterprises LLC$210
- Nevro Corp.$187
- Dexcom, Inc.$170
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,67398%
- Education$572%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $610 |
| Boehringer Ingelheim | 13 | $231 |
| Lilly USA, LLC | 18 | $214 |
| RGH Enterprises LLC | 8 | $210 |
| Nevro Corp. | 8 | $187 |
| Dexcom, Inc. | 14 | $170 |
| Globus Medical | 9 | $165 |
| Tandem Diabetes Care, Inc. | 7 | $134 |
| Medtronic | 3 | $115 |
| Bayer | 6 | $90 |
| Corcept Therapeutics | 5 | $86 |
| Corium, LLC | 3 | $70 |
| Sequel Med Tech, LLC | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Abbott | 3 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 1 | $34 |
| Novo Nordisk | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 2 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Insulet Corporation | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| BETA Bionics, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Merck | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$2,729 in reported general payments places this provider in the 80th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 512 | $591,245 |
| OzempicSemaglutide | 480 | $512,437 |
| FarxigaDapagliflozin Propanediol | 349 | $254,865 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 81 | $120,417 |
| JardianceEmpagliflozin | 116 | $105,584 |
| RybelsusSemaglutide | 75 | $103,723 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 76 | $100,430 |
| Gvoke Hypopen 2-PackGlucagon | 127 | $83,638 |
| Tresiba Flextouch U-200Insulin Degludec | 82 | $69,836 |
| Humalog Kwikpen U-200Insulin Lispro | 34 | $52,063 |
| JanuviaSitagliptin Phosphate | 38 | $39,458 |
| Tresiba Flextouch U-100Insulin Degludec | 53 | $29,038 |
| TrulicityDulaglutide | 28 | $26,722 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 218 | $21,706 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $18,151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog, Insulin Lispro | $214 | $639,097603 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $27 | $636,818587 claims |
| AstraZenecaFarxiga | $610 | $254,865349 claims |
| Boehringer IngelheimJardiance | $231 | $105,584116 claims |
| MerckJanuvia | $13 | $39,45838 claims |
| Sanofi-aventis U.S. LLCLantus | $34 | $2,31123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,415 family providers in Alabama.
Other family in Dothan
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.